Faculty of Medicine, University of Colombo

Better Choice Research Partner, Aimia Pet HealthCo Inc., Signs R&D Partnership Agreement for Development of GLP1 Supplement for Pets

Retrieved on: 
Wednesday, November 8, 2023
Faculty, NYSE, São Paulo, Federal University of Rio Grande do Sul, Obesity, Cat, Université de Montréal Faculty of Veterinary Medicine, Pet, Doctor of Philosophy, Rio, UNESP, APH, Veterinary medicine, MOU, Medical school, Faculty of Medicine, University of Colombo, University of São Paulo, UFRGS, Animal, University, Universidad, Overweight, Better Choice Parking, Pain management, GLP1, Dog, MS, Physiology, Medicine, Pharmacology, Anesthesia

TAMPA, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, and its research partner, Aimia Pet HealthCo Inc. (APH), today announced that APH has signed a memorandum of understanding (MOU) with Dr. Nadia Crosignani for the development of a GLP1 supplement for pets.

Key Points: 
  • TAMPA, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, and its research partner, Aimia Pet HealthCo Inc. (APH), today announced that APH has signed a memorandum of understanding (MOU) with Dr. Nadia Crosignani for the development of a GLP1 supplement for pets.
  • The MOU sets out the basis for Dr. Crosignani to commence research and development of a GLP1 supplement for use in companion animals.
  • In addition, Dr. Crosignani has a post-doctorate degree from UNESP, Faculty of Medicine, researching in the field of pain management.
  • We see the use of the GLP1 supplement as a significant opportunity for the pet health industry and are assembling top tier partners to help Better Choice and our brands, including Halo, become pioneers in this sector,” commented Mike Young, Chairman of the Board for Better Choice.

Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Circumferential Catheter System to be Featured in a Presentation at the Global EP Summit

Retrieved on: 
Friday, September 29, 2023
Biotechnology, Health Technology, Health, Medical Devices, Central Florida, Fellow, Femoral vein, Atrial fibrillation, Faculty of Medicine, University of Colombo, Associate, AF, AdventHealth, Medical device, Electrophysiology

Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced its nsPFA technology will be featured in a presentation at the Global EP Summit 2023 in Cleveland, OH from September 29th to 30th, 2023.

Key Points: 
  • Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced its nsPFA technology will be featured in a presentation at the Global EP Summit 2023 in Cleveland, OH from September 29th to 30th, 2023.
  • “I believe Pulse Biosciences’ nsPFA circumferential catheter system represents a novel and highly differentiated solution for the treatment of atrial fibrillation by electrophysiologists.
  • Consistently performing circumferential ablations of targeted pulmonary veins in a single shot, in approximately 5 seconds with nsPFA, not only represents a significant time advantage, but also a simpler procedure that could lead to improved patient outcomes,” said Dr. Usman Siddiqui, Chief of Electrophysiology at Advent Health, Director of EP at Advent/Nicholson Center, Associate Professor of Medicine University of Central Florida.
  • “I look forward to detailing both the utility of the novel energy modality and its potential impact on the treatment of AF with fellow EPs at the Global EP Summit.”
    During this presentation, Dr. Usman Siddiqui will be discussing Pulse Biosciences’ nsPFA technology and catheter system.

The Grand Hamdan Award goes to two scientists in Australia

Retrieved on: 
Tuesday, October 18, 2022
TRI, Immunology, Infection, Faculty of Medicine, University of Colombo, Organization, Medical research, Late, University, Faculty, Human papillomavirus infection, Center, CEO, Cervical cancer, Research, University of Queensland, Translational Research Institute, Award, HPV, Medical device, Pharmaceutical industry, Medicine

Late Dr. Jian Zhou was the Lion Principal Research Fellow, Chair HPV Structure Protein Laboratory at the Centre for Immunology and Cancer Research of the University of Queensland Faculty of Medicine, Brisbane, Australia.

Key Points: 
  • Late Dr. Jian Zhou was the Lion Principal Research Fellow, Chair HPV Structure Protein Laboratory at the Centre for Immunology and Cancer Research of the University of Queensland Faculty of Medicine, Brisbane, Australia.
  • Prof. Ian Frazer says that we could not have achieved this historic breakthrough without the contribution of Dr. Jian Zhou, who sadly passed away in 1999.
  • Sheikh Hamdan bin Rashid Al Maktoum Award for Medical Sciences is a non-profit organization that honors researchers worldwide who carry out distinguished medical research to serve humanity.
  • Also, the Award stimulates scientific interaction and enriches scientific research among doctors in the UAE and overseas.